STORM Therapeutics
Dr. Holz joined STORM Therapeutics as Chief Medical Officer in June 2020. Dr. Holz has over 25 years’ experience in pharmaceutical drug development in Europe and North America. She has held executive managerial positions at international pharmaceutical & biotech companies Ablynx, GPC-Biotech, Gilead Sciences, Bristol-Myers Squibb and LEO Pharma. Dr. Holz has worked on more than 50 disease targets at various stages of clinical validation across oncology, immunology and other indications.
Dr. Holz is a medical advisor to the European Commission and is member of various medical associations such as ASCO, ESMO and SITC. She provides clinical advice and part-time CMO support for SMEs and biotech companies. Dr. Holz received her PhD in Haematology Oncology from the University Marburg, Germany in 1995.
This person is not in any offices
STORM Therapeutics
1 followers
STORM Therapeutics is a pioneer in the field of RNA epigenetics. We are an emerging biotechnology company in Cambridge, UK, focused on developing small molecule inhibitors of RNA-modifying enzymes for the treatment of cancer.